Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.
With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.
How one company seeks to provide hope to cancer patients through more effective treatments.
original article: FDA Grants Fast Track Designation to Quaratusugene Ozeplasmid Immunogene Therapy Plus Pembrolizumab for NSCLC (cancernetwork.com)
original article: FDA Grants Fast Track Designation for Reqorsa in Combination with Keytruda for NSCLC (pharmacytimes.com)
original article: FDA grants Fast Track status to Genprex’s drug for NSCLC treatment (pharmaceutical-technology.com)
original article: FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC (onclive.com)
Genprex's President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.
As a disease involving mutated genes, cancer has always been a key target for emerging gene therapy technologies.
What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Designed and Secured by Barsec